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Polymorphisms for Aromatic Amine
Metabolism in Humans: Relevance for Human
Carcinogenesis
by Fred F. Kadlubar,' Mary Ann Butler,1 Keith R.
Kaderlik,' Hsien-Chang Chou,' and Nicholas P. Lang2
The metabolic pathways associated with carcinogenic aromatic amines in humans provide an excellent
example ofpolymorphisms that appear to be relevant to human carcinogenesis. In this regard, theN-acetyla-
tion of arylamines and the O-acetylation of their N-hydroxy metabolites are catalyzed preferentially by a
genetically polymorphic acetyltransferase, high activity ofwhich has been correlated with decreased riskfor
urinary bladder cancer and increased susceptibility to colorectal cancer. Cytochrome P450IA2, the principal
liver enzyme involved in aromatic amine N-oxidation, exhibits a wide interindividual variation that appears
trimodal inseveralpopulations andisclearlyinduciblebycigarettesmokingandprobablyotherhostfactorsas
well. UDP-Glucuronosyltransferases, which catalyze theN-glucuronidation ofN-hydroxyarylamines and are
likely to be responsible for their transport to the colon, show widely varied but unimodal distributions in
humans. Incontrast, humanliversulfotransferase activityforN-hydroxyarylamines, whichwouldbeexpected
to decrease theirtransportthroughthe circulation, iscatalyzedby apolymorphic enzyme(s) that is expressed
at higher levels in blacks, as compared to whites, and could contribute to their relatively lower incidence of
urinarybladdercancer.Peroxidative activationofaromaticaminescanalsooccur,especiallyfromprostaglan-
din Hsynthase in the urinarybladder and myeloperoxidase in the lungs ofcigarette smokers, and both show
considerable individual variability, apparently due to the extent oftissue inflammation. In a pilot study, we
have examined two ofthese polymorphisms, acetyltransferase and cytochrome P450IA2, in colorectal cancer/
polyp cases (n = 38) and controls (n = 100) and found that individuals who are both rapid acetylators and
rapidN-oxidizers are indeed more prevalent (p < 0.008) among cases (37%) than among controls (16%).
Introduction
Thewidevariation in carcinogen metabolism in humans
has long been regarded as an important determinant of
individual susceptibility to chemical carcinogenesis (1,2).
In the case of aromatic amine carcinogens, it has become
apparent that the biochemical basis for these differences
may be the polymorphic distribution of specific carcino-
gen-metabolizing enzymesinvolvedintheiractivation and/
or detoxification (3,4). These polymorphisms can arise
from both heritable and environmental factors, which can
be assessed in epidemiological studies. With the recent
development of methods for metabolic phenotyping and
genotyping, together with current techniques to detect
carcinogen-protein and carcinogen-DNA adducts in hu-
mantissues, itshould nowbepossible to assess much more
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accurately both susceptibility and exposure that may be
truly predictive ofindividual cancer risk.
The role ofaromatic amines has been well established in
cancerofthehumanurinarybladder. Intheearlypartofthis
century, industrial exposures to 4-aminobiphenyl (ABP),
2-naphthylamine, andbenzidinewereclearlyassociatedwith
ahighincidenceoftransitionalurothelial-cellcarcinomas(5);
recently, occupational exposures to 4,4'-methylenebis(2-
chloroaniline) (MOCA) and o-toluidine have alsobeen corre-
lated with increased bladder cancer risk (6,7). Likewise,
cigarette smoking has often been implicated as a causative
factor in urinary bladder carcinogenesis (8); and this asso-
ciationhasbeensupportedbyfindings thataromatic amines
suchasABParepresentinnanogramquantities incigarette
smoke (9) and that smokers have much higherlevel ofaro-
matic amine-hemoglobin adducts than nonsmokers (10).
Recently, we showed that several smoking-related DNA
adductspresentinhumanurothelium arecharacteristic of
aromatic amine-C8-deoxyguanosine adducts and identi-
fied N-(deoxyguanosin-8-yl)-4-aminobiphenyl as a major
adduct (11).
An increasing body of evidence indicates that aromatic
amines may play a significant role in the etiology ofhumanKADLUBAR ETAL.
colorectal cancer. Greater susceptibility to this disease has
long been associated with dietary factors, including con-
sumption of well-done red meats (12) and of cured and
smoked meats (13). Duringthe cookingprocess, pyrolysis of
meat liquids can result in the formation of mutagenic and
carcinogenic heterocyclic amines (14), such as 2-amino-3-
methylimidazo[4,5-J]quinoline (IQ), 2-amino-3,8-dimeth-
ylimidazo-[4,5-flquinoxaline (MeIQx), 2-amino-1-methyl-6-
phenyHmidazo[4,5-b]pyridine(PhIP),and2-amino-6-methyl-
dipyrido[1,2-a:3',2'-d]imidazole (Glu-P-1). Several of these
aromaticaminesareknowntoinducetumorsinexperimental
animals inavarietyoftissues,notablytheliverandintestine
(15); and they have also been detected in urine of
individuals who consume a normal, meat-containing diet
(16). Theirmetabolic activation pathways havebeen exten-
sively studied inrodents, and we haverecently shownthat
human liver and colon tissues possess comparable enzyme
systems (17).
The involvement of aromatic amines in other human
cancers is unclear, although limited epidemiological evi-
dence suggests a role in cancers of the lung, liver, colon,
and pancreas (18-20). In this regard, ABP-DNA adducts
have been detected at high levels in the lungs of both
smokers and nonsmokers (20).
Inthisreport,weexaminethebiochemicalproperties of
themajoraromatic aminemetabolizing enzymesinhuman
tissues, their polymorphic distribution in human popula-
tions, and the implications ofthese findings for individual
susceptibility to aromatic amine-induced cancers. Thedis-
cussion will include the acetyltransferases, cytochromes
P450, UDP-glucuronosyltransferases, sulfotransferases,
and peroxidases. Finally, the application of current phe-
notyping methods in an on-going epidemiological study
will be discussed.
Acetyltransferases
Acetyltransferase activity in humans is coded by two
distinct genes, designated NATi and NAT2 (21-23). The
formeractivityappearstobemonomorphicallydistributed
in humans, while the latter exhibits a polymorphism that
allows the detection of phenotypically slow and rapid
metabolizers. The polymorphism of NAT2 arises from
point mutations in coding and noncoding regions that can
result in decreased expression, low activity, or enzyme in-
stability. In human colon mucosa, high activities of both
NATI and NAT2 have been found; however, onlyNAT2 is
expressed intheliverand athighlevels inrapid acetylator
individuals (17). At low substrate concentrations, NATI
selectively catalyzes the N-acetylation ofp-aminobenzoic
acid, while NAT2 selectively N-acetylates sulfamethazine
and several arylamine drugs and carcinogens (20). NAT2
can also catalyze the O-acetylation of the N-hydroxy-
arylaminemetabolites,whichresults intheirconversionto
an ultimate carcinogen that forms arylamine-DNA ad-
ducts (24). Overlapping substrate specificity between
NATi and NAT2 is also apparent in the case of 2-ami-
nofluorene N-acetylation and the O-acetylation ofcertain
N-hydroxyarylamines (17,21,24).
TheNAT2polymorphismcanhaveasignificanteffecton
individual susceptibility to aromatic amine-induced can-
cers. Forurinarybladdercarcinogenesis, N-acetylation of
arylamines such asABP and 2-naphthylamine represents
a competing pathway for N-oxidation, a necessary meta-
bolic activation step occurring in the liver. The unconju-
gatedN-hydroxymetabolitecanthenenterthecirculation,
undergorenalfiltration, andbetransportedtotheurinary
bladder lumen, where reabsorption and covalent binding
to urothelial DNAcan occur (25). Consequently, anumber
ofstudies have demonstrated increased cancer risk in phe-
notypically slow acetylators with documented occupational
exposure to arylamines (26). Moreover, among cigarette
smokers, the slow acetylator individual forms significantly
higher levels ofABP-hemoglobin adducts (27).
Two of three reports on human colorectal cancer,
(13,28,29) havefoundthatrapidacetylators are overrepre-
sented among cases as compared to controls. In this
context, we have shown that the heterocyclic amines,
whichhavebeenimplicated as ariskfactorinthis disease,
are poor substrates for N-acetylation in human liver;
however, they readily undergo hepatic N-oxidation and
subsequent N-glucuronidation (vide infra), resulting in
conjugated N-hydroxy metabolites that can be trans-
ported to the colonic lumen, hydrolyzed by ,B-glucuroni-
dases, and reabsorbed. In colonic mucosa, the N-hydroxy
derivatives are good substrates for O-acetylation, which
results in reactive N-acetoxyarylamines that form
covalentDNAadducts (17).Thus, the associationofhigher
risk for colorectal cancerwith rapid acetylator phenotype
is consistent with both an etiologic role for heterocyclic
amines and theirmetabolic activation pathwayin humans.
Cytochromes P450
The cytochromes P450 (CYPs) in humans consist of at
least 20 different proteins that are coded by a multi-gene
superfamily (30). Studies conducted thus far suggest,
however, thatonlyaboutfourisoforms ofthese CYPs play
a major role in carcinogen metabolism (31). These are
CYPlAl, CYP1A2, CYP2E1, and CYP3A4. In this regard,
polycyclic aromatic hydrocarbons appear to be activated
principally by CYPlAl and CYP3A4; low-molecular-
weight nitrosamines, hydrazines, halogenated hydrocar-
bons, and vinyl compounds by CYP2E1; mycotoxins by
CYP3A4; and most carcinogenic aromatic amines by
CYP1A2 (31). CYP1A2 catalyzes the N-oxidation ofABP,
2-naphthylamine, IQ, MeIQx, PhIP, Glu-P-1, and avariety
ofother heterocyclic and bicyclic aromatic amines. 6-Ami-
nochryseneandMOCA,however, areN-oxidizedprimarily
by CYP3A4. Arylamine N-oxidation by human CYPlAl
may also occur to a limited extent; however, comparison
withdatainexperimentalanimals(32)indicatesthatarole
forCYPlAl indetoxificationthroughring-hydroxylationis
more likely.
CYP1A2, CYP2E1, and CYP3A4 are expressed at high
levels in humanliver;whileCYPlA1 appears tobepresent
only at low levels in human lung, placenta, and lympho-
cytes; and CYP3A4isfound atlowlevels in human intesti-
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nal mucosa (31). Each of these CYPs appears to exhibit
wide interindividual variation, and evidence for their in-
ducibility by drugs and by environmental and dietary
factors has been reported. Whether or not genetic poly-
morphisms exist is as yet unknown, although an appar-
entlybimodaldistributionforCYP1A2inlivermicrosomes
has been described (33,34). Since the identification of
caffeine 3-demethylation (CYP1A2), chlorzoxazone 6-hy-
droxylation (CYP2E1), and cortisol 6I8-hydroxylation
(CYP3A4) as selective assays forthese CYPs (31), studies
are currently in progress in several laboratories on the
application of phenotyping (and genotyping) methods to
human populations.
Caffeine has been used for the determination of aro-
matic amine acetylationphenotype (35) onthebasis ofthe
urinary ratio of two metabolic end-products, 5-acetyl-
amino-6-formylamino-3-methyluracil (AFMU) and
1-methylxanthine (1X). Sincecaffeine3-demethylationwas
found to be selectively catalyzed by CYP1A2 and also
represents the major pathway for caffeine disposition in
humans (36), we decided to examine its use for phenotyp-
inghuman populations to assess theirproficiencyforboth
aromatic amine acetylation and N-oxidation in vivo. The
analytical procedure thatwe have developedis amodifica-
tion of the acetylator phenotyping method (35) and
involves high-performance liquid chromatography with
quantificationbydiodearraydetection. Inorderto selecta
urinary ratio that accurately reflects caffeine 3-demeth-
ylation (and aromatic amineN-oxidation), apharmacokinetic
studywas carried outin 12individuals inwhomthelevels of
caffeine and 15 of its metabolites in blood and urine were
measured over a 48-hr period after caffeine dosing (3 mg/
kg). The results indicated that the urinary ratio of [1,7-
dimethylxanthine (17X) + 1,7-dimethyluric acid (17U)1/caf-
feine(137X),obtained4-5hraftercaffeineingestion,isbetter
correlated (r = 0.73; p = 0.007) with the proficiency ofcaf-
feine3-demethylation (K137X+17x/K137Xurine) than arethe
ratios of17X/137X (r = 0.54; p = 0.07) or [AFMU + 1X +
1Ul/17U (r = 0.33; p = 0.30), which were suggested pre-
viouslyforthis purpose (37,38).
Metabolic phenotyping of cytochrome CYP1A2, using
the urinary ratio of (17X + 17U)/137X, has now been
carried out on several groups of normal subjects from
Arkansas (n = 100), Italy (n = 95), and China (n = 39).
Pearson's chi-squared testofnormalityindicates thatthis
urinary ratio is not normally distributed (p < 0.01) in any
of these populations. Moreover, probit analysis and fre-
quency plots show apparent trimodal distributions with
different cut-offpoints in smokers andnonsmokers. These
data provide strong evidence that CYP1A2 is induced in
humans by cigarette smoking and are consistent with
results from previous studies that show that smoking
increases caffeine clearance (39), phenacetin O-deethyla-
tion (40) and levels ofCYP1A2 in human livermicrosomes
(33,34). Moreimportantly, the apparenttrimodal distribu-
tion allows for the designation of slow, intermediate, and
rapid metabolizers within these populations. These dif-
ferences may arise from a genetic polymorphism in the
CYP1A2 gene or in a regulatory gene, from individual
differences in exposure toinducingagents, aswell asfrom
other epigenetic factors. Nevertheless, although it is not
yet known ifthispolymorphism represents agenotypic or
phenotypic determinant, the caffeine metabolic phenotyp-
ingprocedureis suitableforuseinepidemiological studies
andmayprovideameansforassessingtheroleofaromatic
amines in humancarcinogenesis.
UDP-Glucuronosyltransferases
The human UDP-glucuronosyltransferases (UGTs)
appear to consist of two multigene superfamilies, desig-
nated UGTMA and UGT2A/UGT2B (41). These trans-
ferases exhibit distinct but overlapping substrate speci-
ficity and are known to catalyze the glucuronidation of a
variety of phenols, arylamines, steroids, and bilirubin.
Enzymatic activity is highest in the liver, followed by
kidney and intestinal mucosa (42). We have shown that
human liver microsomes can catalyze the N-glucuronida-
tion of several N-hydroxyarylamines, including those
derivedfromABP and2-naphthylamine (43), andfromIQ,
MeIQx, PhIP, and Glu-P-1 (44). By comparison with the
findingsfromanimalstudies (43,45),theseresults suggest
that the N-hydroxyarylamine N-glucuronides may also
serve as proximate carcinogens in humans as a conse-
quence of their transport via the urine or bile to the
carcinogen-target tissue-the urinary bladder or colon,
respectively. Hydrolysis of the N-glucuronide in the uri-
nary bladder lumen under slightly acidic conditions can
regenerate the N-hydroxyarylamine and the correspond-
ing arylnitrenium ion, which can react with DNA in the
urothelium (25,43). In the colonic lumen, ,B-glucuronidase
can cleave the glucuronide to yield the N-hydroxy-
arylamine, which can then undergo further activation by
O-acetylation in the colonic mucosa [(17) vide supra].
In human liver, at least five different UGT gene prod-
ucts are expressed (46). At present, it is not known which
UGT isozyme is responsible for N-glucuronidation of
N-hydroxyarylamines. Studies (K. Kaderlik, B. Burchell,
and F. F. Kadlubar, unpublished data) usingcultured cells
that express cloned human UGTlA1 failed to show any
activity for the N-hydroxy derivatives ofGlu-P-1 or PhIP.
Withavarietyofsubstrates, awidevariation(4-to19-fold)
in liver UGT activity has been reported (47-49); however,
thedistribution appearstobeunimodal (49). Exceptinthe
case of UGT1A2, which is associated with defective
bilirubin conjugation diagnostic ofthe Crigler-Najar syn-
drome (50), there is asyetno evidence for apolymorphism
in human populations. Since UGT activities are known to
be inducible in humans by cigarette smoking and by
barbiturates (50), however, characterization ofthis activi-
ty may allow an assessment of host factors that could
affect susceptibility to aromatic amine induced carcino-
genesis in humans.
Sulfotransferases
Phenol sulfotransferases, which catalyze the sulfate
conjugation of catechol and phenolic drugs and other
xenobiotics, have been studied in several human tissues,
includingtheliver, smallintestine, cerebral cortex, kidney,
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and blood platelets (42,51). Two forms ofsulfotransferase
have been characterized: a thermolabile (TL) form that
catalyzes the sulfation of dopamine and other phenolic
monoamines andisrelativelyresistanttoinhibition by2,6-
dichloro-4-nitrophenol; and athermostable (TS) formthat
catalyzes the sulfation of a variety of phenols, such as
p-nitrophenol, and is highly sensitive to 2,6-dichloro-4-
nitrophenol inhibition. The TL and TS enzymes are inde-
pendently regulated (52) and appear to be expressed at
highest levels in the liver, butthe levels canvarywidelyin
tissues fromdifferentindividuals. Forexample, thereis no
correlation betweenlevels ofTL activityinplatelets andin
liver and small intestine from different individuals; while
levels ofplatelet, liver, and intestinal TS activity are well
correlated in this regard (53,54). Furthermore, several
studies nowindicate thatthe TS sulfotransferase exhibits
ageneticpolymorphisminhumans thatispolygenic andis
responsible for regulation ofboth the level ofactivity and
the thermal stability of the enzyme (55-57). A racial dif-
ference in TS sulfotransferase activity has also been
reported, themeanlevel ofplatelet activityinblacksbeing
about 2-fold higher than that in whites (58).
We recently examined the role of the liver TS and TL
sulfotransferases in the conjugation of the N-hydroxy
metabolites of several carcinogenic aromatic and hetero-
cyclic amines (59).N-Hydroxy-2-aminofluorene, N-hydroxy-
ABP, N-hydroxy-MOCA, and, to lesser extent, N-hydroxy-
PhIP and N-hydroxy-Glu-P-1 were substrates formetabolic
activation; but no activity was detected for the N-hydroxy
derivatives of IQ and MeIQx. Studies of inhibition and
thermal stability further indicated that it was the human
liverTS sulfotransferase thatwasprimarilyresponsible for
these activities, while the TL enzyme may also play a sig-
nificantroleinthemetabolic activation ofN-hydroxy-MOCA,
N-hydroxy-PhIP, and N-hydroxy-Glu-P-1.
Although the hepatic sulfate conjugation ofN-hydroxy-
arylamines results in formation of a reactive electrophile
and could increase the riskforinitiation ofliverneoplasia,
thefacile solvolysis oftheseesterstophenolicsulfates also
represents a major detoxification pathway and usually
accountsforthemajorexcretionproductofaromaticamine
bladder carcinogens in experimental animals (60). Thus,
higher levels ofhepatic sulfotransferase in humans would
be expected to decrease the amount of free N-hydroxy
metabolite available to enter the circulation and be trans-
ported to the urinary bladder (25). Accordingly, the TS
sulfotransferase polymorphism might be expected to re-
sult in individual differences in susceptibility to aromatic
amine-inducedurinarybladdercarcinogenesis. Inparticu-
lar, the higher levels of TS sulfotransferase in American
blacks could accountfor theirobserved lowerrelative risk
to cigarette-smoking related urinary bladder cancer (61).
Hepatic sulfotransferase activity could also serve as a
competing pathway for the N-glucuronidation of N-hy-
droxyarylamines. The relatively poor substrate specificity
ofthe phenol sulfotransferases fortheN-hydroxyhetero-
cyclic amines suggests, however, thatTS sulfotransferase
polymorphism is unlikely to be a risk factor for aromatic
amine-induced colorectal cancer.
Peroxidases
Another pathway for the activation of aromatic amines
may occur in human extrahepatic tissues and involves
peroxidative metabolism to reactive intermediates that
formcovalentadductswithDNAandproteins.Atpresent,
two separate enzyme systems have been implicated: pros-
taglandin H synthase and myeloperoxidase. Prostaglan-
dinHsynthase hasbeenmeasuredbyboth enzymaticand
immunochemical criteria in human urinarybladder, pros-
tate, and lung; and it has been shown to mediate the co-
oxidation of benzidine, ABP, 2-naphthylamine, Glu-P-1,
and IQ (62). The levels of this peroxidase in most tissue
samples examined were comparable to that observed in
experimental animals, where the contribution of this
activationpathwaytoDNAadductformationappearstobe
minor (25). However, because levels of prostaglandin H
synthase areincreasedbyphysiological responses,includ-
ing inflammation, the tissue peroxidase levels in some
individuals are20-to100-foldhigher, andtheycouldplaya
major role in aromatic amine activation. This may be
particularlyrelevantinthecaseofurinarytractinfections,
including schistosomiasis, which have long been estab-
lished as high risk factors for bladder cancer (63).
Human myeloperoxidase, which is present in neu-
trophils and monocytes, is also stimulated by the inflam-
matoryresponse. Inaddition,thisenzymehasbeenshown
to carry out the metabolic activation ofseveral arylamine
drugs and carcinogens (64,65) and has been suggested to
be involved in several kinds of bone marrow toxicity
induced by drugs such as procainamide, dapsone, and
sulfamethoxazole (66,67). Recently, we characterized a
peroxidase in human lung microsomal preparations that
activates benzidine, ABP, 2-naphthylamine, 2-amino-
fluorene, and 4,4'-methylenebis(2-chloroaniline) and
appears tobeidenticalwithmyeloperoxidase, onthebasis
of cofactor requirements, inhibition, and solubilization
with high salt (S. J. Culp and F. F. Kadlubar, unpublished
studies). This activity varied by 10-fold in lung samples
from smokers and ex-smokers and appears to be due to
massive infiltration of neutrophils into peripheral lung
tissue (68) around the particulate matter arising from
deposition ofcigarette tar. While this peroxidase activity
is apparently a consequence of cosedimentation with the
microsomal fraction of lung homogenates, it does repre-
sent the highest peroxidase activity ever observed in a
mammaliantissue anditmayhaveimportanttoxicological
significance in the extracellular matrix.
Acetyltransferase and CYP1A2
Polymorphism in Patients
with a History of Colorectal Cancer
and Polyps
The recent development of a noninvasive caffeine phe-
notypingmethod for both acetyltransferase and CYP1A2
now allows for epidemiological studies on two ofthe poly-
morphic enzymes involved in aromatic amine metabolism.
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Inviewofthepossibleroleofheterocyclicaromaticamines
inthe etiologyofhumancolorectalcancer(videsupra),we
decided to examine the prevalence of rapid and slow
metabolizers ofacetyltransferase and CYP1A2 in a case-
control study. The control group was recruited from cen-
tral Arkansas by telephone using random-digit dialing,
and was matched for age, sex, ethnicity, and smoking
status.Becausecolonpolypsareregardedaspreneoplastic
lesions,weelectedtoincludepatientswithpolypswith the
colorectal cancer cases and then stratify our analysis by
diagnosis. Once patient consent had been obtained, the
subjectwasprovidedwithwritteninstructions,aschedule,
a modified "Health Habits and History Questionnaire,"
and a quantity of coffee (two packets of Maxwell House
Instant). Afollow-up phone callwas used to answer ques-
tions, reinforce instructions, and improve participation.
When the subject arrived to provide a 4- to 5-hr urine
sample,thequestionnairewasreviewedbythestudynurse
for completeness ofresponse.
At present, 100 control subjects, 20 colorectal cancer
patients, and 18 polyp patients have been entered into the
study. Urine samples from these individuals were ana-
lyzed by high-performance liquid chromatography to
determine AFMU/1X for acetyltransferase phenotyping
and (17X + 17U)/137X for CYP1A2 phenotyping. Probit
analysis of values obtained from the control group pro-
vided cut-off points of 0.6 for AFMU/1X and of 10.0
(nonsmokers) and 18.7 (smokers) for (17X + 17U)/137X.
Control subjects consisted of 42% rapid acetylators and
43% rapid N-oxidizers; while cancer and polyp patients
combined consisted of 61% rapid acetylators and 55%
rapid N-oxidizers. Using a chi-square test with 2 x 2
contingency tables, a trend toward an increased propor-
tionoftherapidacetylatorphenotype (p = 0.05)andrapid
CYP1A2 phenotype (p = 0.19)was apparent forcolorectal
cancerandpolyppatients. Acomparison oftheprevalence
of individuals who are both rapid acetylators and rapid
N-oxidizers,however,showedthat16%ofthecontrols,33%
of the polyp patients, and 40% of the colorectal cancer
cases possess this rapid-rapid phenotype (37% of the
polyp and cancer cases combined). This difference is
highly significant (p = 0.014 for cancer cases; p = 0.008
for combined) and provides evidence that metabolic poly-
morphisms for foodborne carcinogenic heterocyclic amines
can be used to predict individual susceptibility to colorec-
talcarcinogenesis.
This manuscript was presented at the Conference on Biomonitoring
andSusceptibilityMarkers in Human Cancer:Applications inMolecular
Epidemiology and Risk Assessment that- was held in Kailua-Kona,
Hawaii, 26 October-1 November 1991.
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